Search hospitals > Kansas > Olathe
Olathe Health Cancer Center
Claim this profileOlathe, Kansas 66061
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
144 reported clinical trials
26 medical researchers
Summary
Olathe Health Cancer Center is a medical facility located in Olathe, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Olathe Health Cancer Center is involved with conducting 144 clinical trials across 373 conditions. There are 26 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Jun ZhangHouston Methodist Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
23 reported clinical trials
38 drugs studied
Gary C. DoolittleHaysMed University of Kansas Health System3 years of reported clinical research
Studies Cancer
Studies Melanoma
18 reported clinical trials
29 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
18 reported clinical trials
30 drugs studied
Andrea D. JewellUniversity of Kansas Cancer Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
38 drugs studied
Clinical Trials running at Olathe Health Cancer Center
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Renal Cell Carcinoma
Pancreatic Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Olathe Health Cancer Center?
Olathe Health Cancer Center is a medical facility located in Olathe, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Olathe Health Cancer Center is involved with conducting 144 clinical trials across 373 conditions. There are 26 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.